Summary Biotech major CSL Limited upgrades its guidance for FY21, anticipates revenue growth in the range of 6-10% over FY20. The Company has narrowed its NPAT growth range from 0%-8% to 3%-8%. CSL now anticipates NPAT in the range US$2.170-US$...
Summary SUDA Pharmaceuticals (ASX:SUD) has recently published its October 2020 newsletter for shareholders, outlining developments around its key projects – ZolpiMist® and anagrelide. Lately, SUDA has made significant progress with re...
Summary The Australian cannabis market was relatively unscathed by COVID-19 and is anticipated to grow in the future through combined efforts of cannabis agencies. Althea’s Canada-based Peak Processing Solutions recently obtained its Stan...
Summary Supported by an international leadership team with extensive expertise in cancer therapy, Prescient has developed a robust product pipeline, comprising personalised cancer treatments. Prescient’s drug pipeline comprises CAR-T and ...
Summary Focus on the entire Healthcare industry has doubled up, courtesy the covid-19 pandemic The top listed ASX healthcare stocks have been in demand and generating profits despite their volatile trajectory in past CSL recently entered into ...
Summary ASX200 member ResMed Inc is set to announce its results for the 1st quarter of FY2021 on 29 October 2020. The US-headquartered medical equipment player is working with various stakeholders to deliver ventilation therapy for the treatmen...
Summary Creso Pharma secured firm commitments to raise up to ~A$9 million from institutional, professional, as well as sophisticated investors. The funds shall be used for development and accelerating growth across its existing animal and human...
Summary Availability and efficient deployment of sufficient funds is important but strategic stance of a business cannot be ignored. Biotechnology companies such as CSL are continuously spending on R&D and innovating newer products/vaccine ...
The Australian government, to extend support to domestic researchers as well as manufacturers for developing COVID-19 vaccine, is investing ~A$2.3 billion. The government is also entering multiple strategic global partnerships to suppor...
Summary Imugene has attained a core patent in the largest pharmaceutical market of the world. The patent protects its cancer growth factor immunotherapy platform, predominantly unique combination treatments that target members of the IGF-1R and...
Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)
